Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090584 · ClinicalTrials.gov registry record · NA
Behavior Enhances Drug Reduction of Incontinence (BE-DRI)
A NA study, sponsored by Carelon Research.
- Completed
- Registry status
- NA
- Development phase
- 307
- Enrollment target
NCT00090584: Completed NA study, sponsored by Carelon Research.
NCT00090584 is a NA study that has completed, run by Carelon Research. The registered enrollment target is 307 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090584, a NA study, has completed, sponsored by Carelon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 307 participants
- Enrollment target
Study Summary
The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.
Primary Outcome
Proportion of women who meet definition of success: not taking drug or receiving other urge UI therapy (i.e., neuromodulation, botox injections, myomectomy, electrical stimulation, or any intravesical therapy) and not taking a tricyclic antidepressant or duloxetine at 8 months; and a \>70% reduction in number of incontinence episodes as compared to baseline.
Interventions
- DRUG Tolterodine
- BEHAVIORAL Behavioral training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-08 |
| Phase | NA |
What the finished NCT00090584 record still lists
NCT00090584 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which Tolterodine is the first listed.
NCT00090584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00090584 about?
NCT00090584 is a clinical study titled "Behavior Enhances Drug Reduction of Incontinence (BE-DRI)". The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.
What is the current status of trial NCT00090584?
This trial is currently completed. It is a NA study. The enrollment target is 307 participants. The study started on 2004-08. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00090584?
The interventions under investigation include: Tolterodine (DRUG), Behavioral training (BEHAVIORAL).
Who is sponsoring clinical trial NCT00090584?
This trial is sponsored by Carelon Research, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00090584's enrollment target sits among peer trials
307 324th of 2000 higher than 1,677 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia